Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk for developing tuberculosis among anergic patients infected with HIV.
Moreno S, Baraia-Etxaburu J, Bouza E, Parras F, Pérez-Tascón M, Miralles P, Vicente T, Alberdi JC, Cosín J, López-Gay D. Moreno S, et al. Among authors: alberdi jc. Ann Intern Med. 1993 Aug 1;119(3):194-8. doi: 10.7326/0003-4819-119-3-199308010-00003. Ann Intern Med. 1993. PMID: 8100693
A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
Lopez Bernaldo de Quiros JC, Miro JM, Peña JM, Podzamczer D, Alberdi JC, Martínez E, Cosin J, Claramonte X, Gonzalez J, Domingo P, Casado JL, Ribera E; Grupo de Estudio del SIDA 04/98. Lopez Bernaldo de Quiros JC, et al. Among authors: alberdi jc. N Engl J Med. 2001 Jan 18;344(3):159-67. doi: 10.1056/NEJM200101183440301. N Engl J Med. 2001. PMID: 11172138 Free article. Clinical Trial.
Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial.
Miro JM, Lopez JC, Podzamczer D, Peña JM, Alberdi JC, Martínez E, Domingo P, Cosin J, Claramonte X, Arribas JR, Santín M, Ribera E; GESIDA 04/98 Study Group. Miro JM, et al. Among authors: alberdi jc. Clin Infect Dis. 2006 Jul 1;43(1):79-89. doi: 10.1086/504872. Epub 2006 May 31. Clin Infect Dis. 2006. PMID: 16758422 Clinical Trial.
33 results